Chief Executive Officer
CurrentPaint Therapeutics, an Atlanta-based emerging biotech company, is developing a pipeline of conjugate-based drugs using proprietary delivery platforms to enhance distribution and residence time in targeted tissues. Our flagship platform, PulmoPaint™, focuses on lung indications, with other platforms in development for brain and gastrointestinal targeting.Utilizing our proprietary drug targeting algorithm, Paint Therapeutics aims to improve the localization and duration of action of therapeutic agents where they are most needed. Our conjugation-based therapeutic development platforms enable rapid generation of clinical lead compounds from known active drugs.